Eli Lilly to work with Sanford-Burnham on autoimmune diseases

Eli Lilly ($LLY) has signed up to collaborate with researchers at Sanford-Burnham on a new generation of immunological drugs for diseases like lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders. The pact builds on a big commitment that Lilly has in immunology, with 7 programs in the pipeline for psoriasis, rheumatoid arthritis, lupus and inflammatory bowel disease. Sanford-Burnham's work in this area "focuses on cell communication pathways that control the development of lymphocytes, innate and adaptive immune responses, and inflammation." Release